Welcome to our dedicated page for Climb Bio news (Ticker: CLYM), a resource for investors and traders seeking the latest updates and insights on Climb Bio stock.
Climb Bio, Inc. (Nasdaq: CLYM) is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for immune-mediated and B-cell mediated diseases. The CLYM news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow how Climb Bio communicates progress on its pipeline and corporate activities.
News about Climb Bio frequently highlights clinical development updates for its two key programs: budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody. Company announcements have covered initiation and enrollment of Phase 2 and Phase 1b/2a trials of budoprutug in primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, as well as a Phase 1 study of a subcutaneous formulation in healthy volunteers. Climb Bio also reports on preclinical and early clinical data, such as long-term follow-up results in pMN and nonhuman primate data for CLYM116 in IgA nephropathy.
Investors and followers can use this news feed to track regulatory milestones, including investigational new drug and clinical trial application clearances, initiation of Phase 1 studies for CLYM116, and updates on trial site activation and dosing progress. Corporate developments, such as leadership appointments, inducement equity grants under the company’s 2025 Inducement Plan, and participation in healthcare and biotechnology investor conferences, are also common topics in Climb Bio’s news flow.
By monitoring CLYM news on Stock Titan, readers gain a centralized view of Climb Bio’s disclosed clinical timelines, data presentations at scientific meetings, and strategic licensing arrangements related to its pipeline. This context can help users understand how the company’s immune-mediated disease programs are advancing through development.
Climb Bio (Nasdaq: CLYM) is hosting a virtual investor event on October 15, 2024, to provide updates on its development strategy for budoprutug, an anti-CD19 monoclonal antibody. The company has completed its transition to focus on immune-mediated diseases and plans to advance budoprutug to late-phase development in primary membranous nephropathy (pMN) by 2025. Clinical trials for systemic lupus erythematosus (SLE) and immune thrombocytopenia (ITP) are planned for the first half of 2025.
Key highlights include:
- Additional promising data from the Phase 1b pMN study
- Potential for deep and durable B-cell depletion
- Advancement of a subcutaneous formulation
- Planned clinical trials in SLE and ITP
- Cash runway through 2027
The company aims to develop treatments for approximately 50 million patients in the U.S. with immune-mediated diseases.
Climb Bio (Nasdaq: CLYM) has announced that it will present data at the American Society of Nephrology Kidney Week 2024, taking place in San Diego, CA from October 23-27, 2024. The presentation will feature a poster titled 'A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous Nephropathy'.
The presenter will be Dr. Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center, Chief of the Division of Nephrology at St. Peter's Hospital, Chief of Clinical Research at St. Peter's Health Partners, and Clinical Scientist at Massachusetts General Hospital. The poster session, focusing on Membranous Nephropathy, FSGS, and Minimal Change Disease, is scheduled for October 24, 2024, from 10:00 a.m. to 12:00 p.m. PT, with the poster board number TH-PO587.
Climb Bio (Nasdaq: CLYM) has announced its participation in William Blair's Transforming Autoimmune Diseases by Targeting CD19 event. The company will present and host investor meetings at this conference, which is scheduled for Wednesday, October 16, 2024, in New York, NY.
This event focuses on innovative approaches to treating autoimmune diseases, specifically targeting CD19. Climb Bio's involvement suggests their work aligns with this cutting-edge area of medical research. The conference provides an opportunity for Climb Bio to showcase their developments and engage with investors interested in advancements in autoimmune disease treatments.
Climb Bio (Nasdaq: CLYM) has announced a virtual investor event scheduled for October 15, 2024. The event will feature presentations from key management team members and an external expert, providing updates on the company's strategy and focus on developing therapeutics for immune-mediated diseases.
Presenters will include Aoife Brennan (President and CEO), Stephen Thomas (Board Member), Jan Hillson (Senior Clinical Advisor), Nishi Rampal (SVP of Clinical Development), Brett Kaplan (COO), and Frank Cortazar (Director of the New York Nephrology Vasculitis and Glomerular Center).
The event will offer an in-depth review of Climb Bio's lead asset, budoprutug, an anti-CD19 monoclonal antibody designed to treat various immune-mediated diseases. Budoprutug has shown B-cell depletion in early clinical trials. A live webcast and replay will be available on the company's website.